Beyond the outstanding results obtained in CML, imatinib also showed activity against other TKs such as PDGFR and KIT, which led to explore its efficacy in diseases driven by genetic alterations in these receptors including mastocytosis (Akin et al., 2003). Here, PDGFRB is linked to mastocytosis.